Investing.com – Medical Technology company Brainlab AG (TASE:) is exploring options for an initial public offering (IPO) in Frankfurt, according to Bloomberg sources familiar with the situation. The Munich-based company, known for its advances in medical technology, has asked banks for proposals for a possible share sale, the sources said.
The IPO could potentially take place in the second half of 2025, valuing the company at around 2 billion euros ($2.1 billion). However, these plans are still under discussion, and the potential size and timing of the IPO may be subject to change.
In response to a Bloomberg News inquiry, Brainlab said: “Brainlab is keeping all options open to drive long-term growth and maximize shareholder value.” The company clarified that the decision on the IPO has not yet been made and the banks have not been given any powers.
Brainlab, which worked with a consultant to find bank offers to sell the shares, did not disclose any additional details about the potential IPO. The sources, who wished to remain anonymous due to the private nature of the information, stressed that discussions within the company were ongoing.
This article was created with the help of AI and reviewed by an editor. For more information please see our Terms and Conditions.